Actuate Therapeutics, Inc. Common stock (ACTU)vsRegeneron Pharmaceuticals Inc (REGN)
ACTU
Actuate Therapeutics, Inc. Common stock
$1.88
-3.09%
HEALTHCARE · Cap: $47.61M
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.11%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
ACTU
Avoid20
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACTU.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Trading at 11.7x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ACTU
The strongest argument for ACTU centers on Debt/Equity.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : ACTU
The primary concerns for ACTU are Price/Book, Revenue Growth, EPS Growth.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ACTU profiles as a value stock while REGN is a growth play — different risk/reward profiles.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (64/100 vs 20/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Actuate Therapeutics, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious diseases, with a particular emphasis on oncology. The company is advancing its proprietary drug candidates through rigorous clinical trials to tackle significant unmet medical needs and improve patient outcomes. By cultivating a robust pipeline focused on transformative therapeutic solutions, Actuate aims to drive strategic growth and deliver substantial value to its investors, reinforcing its competitive stance within the biotechnology sector.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?